Interpretation of 2019 Hypertension：the Clinical Management of Primary Hypertension in Adults from the National Institute for Health and Care Excellence

doi:10.12114/j.issn.1007-9572.2020.00.174

Abstract

Abstract: Hypertension is a major risk factor for stroke，heart disease，chronic renal failure and other diseases.The timely treatment and comprehensive management of hypertension is of great significance.In August 2019，the National Institute for Health and Care Excellence（NICE） of the United Kingdom issued the Guidelines for Hypertension in Adults：Diagnosis and Management，which was the third update since the 2004 NICE guidelines for the diagnosis and management of hypertension.It not only followed concepts of previous guidelines，but also added some new contents.The new edition of the guidelines for hypertension management provided a comprehensive and detailed description of blood pressure measurement，hypertension diagnosis，cardiovascular risk，target organ damage assessment，antihypertensive treatment，blood pressure monitoring and what kinds of patients require specialist diagnosis and treatment.In particular，the timing of starting drug treatment of hypertension，the choice of treatment options and the concept of comprehensive management are worthy of learning by clinicians.

Key words: Hypertension, Blood pressure determination, Diagnosis, Clinical protocols, Referral and consultation, Guidelines, Adult

摘要： 高血压是脑卒中、心脏病、慢性肾衰竭等疾病的主要危险因素，高血压的及时治疗和综合管理具有重要意义。2019年8月英国国家卫生与临床优化研究所（NICE）发布了成人高血压诊断和管理指南，这是距2004年NICE高血压诊断和管理指南发布后的第３次更新，既沿用了以往的一些理念，又补充了许多新的内容，新版高血压管理指南在血压测量、高血压诊断、心血管风险、靶器官损害评估、降压治疗、血压监测及哪些患者需要专科医生诊治等方面均进行了全面而详细的阐述，尤其在高血压药物治疗的启动时机、治疗方案的选择及综合管理的治疗理念方面，值得临床医生借鉴与学习。

关键词: 高血压, 血压测定, 诊断, 临床方案, 转诊和会诊, 指南, 成年人

CHEN Kai. Interpretation of 2019 Hypertension：the Clinical Management of Primary Hypertension in Adults from the National Institute for Health and Care Excellence　[J]. Chinese General Practice, 2020, 23(16): 1977-1981. DOI: 10.12114/j.issn.1007-9572.2020.00.174.
陈凯. 2019年 NICE《成人原发性高血压管理指南》解读[J]. 中国全科医学, 2020, 23(16): 1977-1981. DOI: 10.12114/j.issn.1007-9572.2020.00.174.

References

［1］刘力生.高血压慢性病管理与展望［J］．中华高血压杂志，2019，27（3）：209-210．DOI：10.16439/j.cnki.1673-7245.2019.03.004．https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFDLAST2019&filename=ZGGZ201903005&v=MTU2NzhSOGVYMUx1eFlTN0RoMVQzcVRyV00xRnJDVVJMT2VaZWRtRnlEbFZyek9QeXJNZExHNEg5ak1ySTlGWVk=.
［2］王丽萍，徐爱军．高血压患者的治疗路径及分级诊疗开展现状研究［J］．中国全科医学，2018，21（10）：1183-1187．DOI：10.3969/j.issn.1007-9572.2018.10.008.
WANG L P，XU A J．Development of hierarchical treatment for hypertension in China：a study based on the analysis of hypertension treatment pathways［J］．Chinese General Practice，2018，21（10）：1183-1187．DOI：10.3969/j.issn.1007-9572.2018.10.008.
［3］郭艺芳.我国高血压防控现状的最新数据与启示［J］．中华高血压杂志，2016，24（6）：504．DOI：10.16439/j.cnki.1673-7245.2016.06.003．https://www.ixueshu.com/document/3f9b08ed883fbef95f66a52e8402630c318947a18e7f9386.html.
［4］程文立．《2018年欧洲高血压管理指南》解读［J］．中国全科医学，2019，22（21）：2519-2523．DOI：10.12114/j.issn.1007-9572.2019.00.224.
CHENG W L．Interpretation of the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension［J］．Chinese General Practice，2019，22（21）：2519-2523．DOI：10.12114/j.issn.1007-9572.2019.00.224.
［5］郭艺芳，张靖．2011英国成人原发性高血压管理指南介绍［J］．中国医学前沿杂志：电子版，2011，3（5）：94-96．DOI：10.3969/j.issn.1674-7372.2011.05.012.
GUO Y F，ZHANG J．The introduction of clinical management of primary hypertension in adults 2011［J］．Chinese Journal of the Frontiers of Medical Science：Electronic Version，2011，3（5）：94-96．DOI：10.3969/j.issn.1674-7372.2011.05.012.
［6］National Institute for Health and Clinical Excellence．Hypertension：the clinical management of primary hypertension in adults
［EB/OL］．（2019-08-28）［2019-09-28］．http://www.doc88.com/p-560147731418.html.
［7］GONZáLEZ-DUARTE A，BARROSO F，MUNDAYAT R，et al．Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey（THAOS）［J］．Auton Neurosci，2019，222：102590．DOI：10.1016/j.autneu.2019.102590.
［8］国家基本公共卫生服务项目基层高血压管理办公室，基层高血压管理专家委员会.国家基层高血压防治管理指南［J］．中国循环杂志，2017，32（11）：1041-1048．http://d.old.wanfangdata.com.cn/Periodical/zgxhzz201711001.
［9］中国高血压联盟，《家庭血压监测指南》委员会．2019中国家庭血压监测指南［J］．中华高血压杂志，2019，34（7）：708-711．DOI：10.3969/j.issn.1000-3614.2019.07.003．http://d.old.wanfangdata.com.cn/Periodical/zgxhzz201907003.
［10］方锐，韩海成，杨勇，等．近20年高血压及靶器官损害风险因素研究趋势可视化分析［J］．中国老年学杂志，2019，39（21）：5140-5147．DOI：10.3969/j.issn.1005-9202.2019.21.002.
FANG R，HAN H C，YANG Y，et al．Visualization analysis on research trends of risk assessment of hypertension and target organ damage in recent two decades［J］．Chinese Journal of Gerontology，2019，39（21）：5140-5147．DOI：10.3969/j.issn.1005-9202.2019.21.002.
［11］严心，陈晓平.高血压前期人群心血管病及靶器官损害的研究进展［J］．中华高血压杂志，2019，27（5）：483-488．DOI：10.16439/j.cnki.1673-7245.2019.05.023．https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFDLAST2019&filename=ZGGZ201905025&v=MjY0MjV4WVM3RGgxVDNxVHJXTTFGckNVUkxPZVplZG1GeURrVzczSlB5ck1kTEc0SDlqTXFvOUhZWVI4ZVgxTHU=（）.
［12］邓阳生，刘全未，赵增光.原发性高血压患者心血管风险水平分层研究［J］．中国现代医学杂志，2016，26（4）：133-137．DOI：10.3969/j.issn.1005-8982.2016.04.029.
DENG Y S，LIU Q W，ZHAO Z G．Cardiovascular disease-related risk levels among patients with essential hypertension［J］．China Journal of Modern Medicine，2016，26（4）：133-137．DOI：10.3969/j.issn.1005-8982.2016.04.029.
［13］来春林，邢金平，刘晓红，等．高血压肾损害危险因素和炎性因子的临床分析［J］．临床心血管病杂志，2017，33（8）：743-746．DOI：10.13201/j.issn.1001-1439.2017.08.007.
LAI C L，XING J P，LIU X H，et al．Analysis of the related clinical factors and inflammatory factors in patient of essential hypertension with chronic kidney damage［J］．Journal of Clinical Cardiology，2017，33（8）：743-746．DOI：10.13201/j.issn.1001-1439.2017.08.007.
［14］麦洁英，廖敏华，黎红.眼底血管变化与原发性高血压分期和危险分层及心脏功能的关系研究［J］．重庆医学，2017，46（10）：1358-1359．DOI：10.3969/j.issn.1671-8348.2017.10.019.
MAI J Y，LIAO M H，LI H．Relationship between change of fundus vascular change with stage and risk stratification of essential hypertension and cardiac function［J］．Chongqing Medicine，2017，46（10）：1358-1359．DOI：10.3969/j.issn.1671-8348.2017.10.019.
［15］周欣，李玉明.限盐补钾，双管齐下：2017年美国高血压指南生活方式干预的新亮点及对我国高血压防控的启示［J］．中华高血压杂志，2017，25（12）：1112-1114．DOI：10.16439/j.cnki.1673-7245.2017.12.009．http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gxyzz201712007.
［16］刘靖.中青年高血压前期需要管理，生活方式干预仍应作为首选［J］．中华高血压杂志，2019，27（4）：301-302．DOI：10.16439/j.cnki.1673-7245.2019.04.001．https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFDLAST2019&filename=ZGGZ201904002&v=MTAwODhIOWpNcTQ5RlpvUjhlWDFMdXhZUzdEaDFUM3FUcldNMUZyQ1VSTE9lWmVkbUZ5RGtWTDNLUHlyTWRMRzQ=.
［17］牟建军.重视生活方式干预，提高高血压管理水平［J］．中华高血压杂志，2014，22（4）：323-325．DOI：10.16439/j.cnki.1673-7245.2014.04.009．http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gxyzz201404006.
［18］董彩霞，荫士安.生活方式干预在控制高血压病中的作用［J］．国外医（卫生学分册），2009，36（6）：387-390．https://www.ixueshu.com/document/a0d7bb67273064f3590a80e8ef5b98ad318947a18e7f9386.html.
［19］黄春虹，庞小清.高血压病患者生活方式的护理干预及效果评价的探讨［J］．中西医结合心血管病电子杂志，2018，6（22）：25-27．DOI：10.16282/j.cnki.cn11-9336/r.2018.22.013.
HUANG C H，PANG X Q．Nursing intervention and effect evaluation of life style of patients with hypertension［J］．Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine，2018，6（22）：25-27．DOI：10.16282/j.cnki.cn11-9336/r.2018.22.013.
［20］彭莉，张学华.社区高血压患者生活方式干预对降压效果的影响［J］．中国临床康复，2004，8（12）：2257-2261．DOI：10.3321/j.issn:1673-8225.2004.12.093．https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFD2004&filename=XDKF200412036&v=MjgyMTQ5R1lvUjhlWDFMdXhZUzdEaDFUM3FUcldNMUZyQ1VSTE9lWmVkbUZ5RGtWcnZCUFNuQWFMRzRIdFhOclk=.
［21］李翠柳，王光亚.恶性嗜铬细胞瘤的诊治进展［J］．东南大学学报（医学版），2016，35（1）：120-124．DOI：10.3760/cma.j.issn.1673-4416.2014.03.031．http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gwyx-mnxt201403031.

[1]	ZHANG Shuai, LI Qin, LI Dongfeng, XIAO Jinping, LI Yunpeng. A Prospective Cohort Study of Solid Fuels Use and Risk of Hypertension in Chinese Older Adults [J]. Chinese General Practice, 2023, 26(32): 4001-4006.
[2]	LU Guangqi, ZHUANG Minghui, ZHU Liguo, GAO Jinghua, WEI Xu, LI Luguang, YU Jie. Interpretation of Best Practices for Minimally Invasive Lumbar Spinal Stenosis Treatment 2.0 (MIST) : Consensus Guidance from the American Society of Pain and Neuroscience (ASPN) in 2022 [J]. Chinese General Practice, 2023, 26(32): 3995-4000.
[3]	HONG Yuchun, WU Hua, DU Yishan, LI Shuran, SUN Wenmin, YE Mingyu, ZHANG Yongjian, LI Yang. Development of General Practice Diagnostic Terminology and Coding and Empirical Study on Its Application [J]. Chinese General Practice, 2023, 26(31): 3896-3901.
[4]	XIAO Liqi, YANG Li, CUI Saixian, ZHANG Yayuan, WANG Yulu, HE Yan. Advances in the Association of High Salt-induced Gut Microbiota Disturbances with Salt-sensitive Blood Pressure [J]. Chinese General Practice, 2023, 26(29): 3704-3709.
[5]	CHENG Xiaoran, ZHANG Xiaotian, LI Mingyue, CHENG Haozhe, TANG Haoqing, ZHENG Huixian, ZHANG Baisong, LIU Xiaoyun. Impact of Chronic Diseases Follow-up on Health Behaviors and Blood Pressure/Glucose Control of Patients with Hypertension and Diabetes in the Context of Treatment-prevention Integration [J]. Chinese General Practice, 2023, 26(28): 3482-3488.
[6]	CHEN Jing, ZOU Tao, ZHAO Danqing, XIAO Ziwen, WU Xianqing, Chinese Medical Association Psychosomatic Medicine Branch Perinatal Mental Disorders Collaborative Group. Expert Consensus on Screening, Diagnosis and Treatment of Perinatal Mental Disorders [J]. Chinese General Practice, 2023, 26(28): 3463-3470.
[7]	BIAN Lili, LI Xiaoxiao, DU Xueping, DAI Qinfang, WU Lin, SONG Beibei. Risk Stratification of Atherosclerotic Cardiovascular Disease and Lipid Goal Attainment in Hypertensive Patients Registered in Community [J]. Chinese General Practice, 2023, 26(27): 3388-3391.
[8]	YIN Zhaoxia, KONG Chongyu, ZOU Xianhui, LI Chuang, HUANG Yin, FENG Yang, WANG Yunfei, GONG Weijie. Traditional Chinese Medicine Disease Spectrum Analysis in Outpatient Clinics of Contracted Residents by Family Doctors in Shenzhen Community Health Service Centers [J]. Chinese General Practice, 2023, 26(25): 3112-3117.
[9]	ZHAO Wei, TANG Rongjie, YANG Shanshan, YANG Fang, SUN Feng, LIAN Qiufang. The Role and Molecules Mechanism of Klotho in Renal Injury in Salt-sensitive Hypertension [J]. Chinese General Practice, 2023, 26(24): 3042-3049.
[10]	ZHANG Yunxu, WANG Tingting, WEI Junling, XING Yanyun, SU Li. A Newly Discovered Disease Affecting Women's Physical and Mental Health: Research Status and Expert Consensus Interpretation of Persistent Genital Arousal Disorder [J]. Chinese General Practice, 2023, 26(23): 2830-2835.
[11]	ZHANG Yanjing, SONG Xiaokun. Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors [J]. Chinese General Practice, 2023, 26(23): 2930-2935.
[12]	ZUO Xu, HUANG Zhaolan, LU Biao. Differences between the First and Another 3-day Blood Pressure Levels and Associated Factors in a Self-reported Non-hypertensive Population Aged 35-64 Years [J]. Chinese General Practice, 2023, 26(22): 2771-2777.
[13]	FENG Jia, WANG Jie, YU Dan, LIU Yongheng, ZHAO Weidong, TIAN Hongyuan. Analysis of Research Hotspots of Multiple Chronic Conditions in the Elderly in 2010-2021 [J]. Chinese General Practice, 2023, 26(21): 2574-2580.
[14]	HU Xiaofei, ZHAO Ping, CAO Tinghua, PENG Lanlan. Study on the Predictive Value of Abdominal Fat Content and Distribution in the Acute Pancreatitis and Its Severity [J]. Chinese General Practice, 2023, 26(21): 2614-2619.
[15]	YU Tong, YANG Yi, DU Shihong, DING Zihao, HONG Xiuqin. Correlation of Shearing Force and Estradiol with Hypertension [J]. Chinese General Practice, 2023, 26(20): 2469-2475,2495.